BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 25319657)

  • 1. Immunosuppressive factor blockade in dendritic cells via siRNAs results in objective clinical responses.
    Sioud M; Mobergslien A; Sæbøe-Larssen S
    Methods Mol Biol; 2015; 1218():269-76. PubMed ID: 25319657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering therapeutic cancer vaccines that activate antitumor immunity.
    Iversen PO; Sioud M
    Methods Mol Biol; 2015; 1218():263-8. PubMed ID: 25319656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients.
    Sioud M; Saebøe-Larssen S; Hetland TE; Kaern J; Mobergslien A; Kvalheim G
    Int J Oncol; 2013 Jul; 43(1):280-8. PubMed ID: 23620105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model.
    Zheng X; Koropatnick J; Chen D; Velenosi T; Ling H; Zhang X; Jiang N; Navarro B; Ichim TE; Urquhart B; Min W
    Int J Cancer; 2013 Feb; 132(4):967-77. PubMed ID: 22870862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new cancer immunotherapy via simultaneous DC-mobilization and DC-targeted IDO gene silencing using an immune-stimulatory nanosystem.
    Zhang Y; Fu J; Shi Y; Peng S; Cai Y; Zhan X; Song N; Liu Y; Wang Z; Yu Y; Wang Y; Shi Q; Fu Y; Yuan K; Zhou N; Joshi R; Ichim TE; Min W
    Int J Cancer; 2018 Oct; 143(8):2039-2052. PubMed ID: 29752722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering better immunotherapies via RNA interference.
    Sioud M
    Hum Vaccin Immunother; 2014; 10(11):3165-74. PubMed ID: 25483669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving Dendritic Cell Cancer Vaccine Potency Using RNA Interference.
    Sæbøe-Larssen S; Sioud M
    Methods Mol Biol; 2020; 2115():249-258. PubMed ID: 32006405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monocyte-Derived Dendritic Cells with Silenced PD-1 Ligands and Transpresenting Interleukin-15 Stimulate Strong Tumor-Reactive T-cell Expansion.
    Van den Bergh JMJ; Smits ELJM; Berneman ZN; Hutten TJA; De Reu H; Van Tendeloo VFI; Dolstra H; Lion E; Hobo W
    Cancer Immunol Res; 2017 Aug; 5(8):710-715. PubMed ID: 28637876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted siRNA silencing of indoleamine 2, 3-dioxygenase in antigen-presenting cells using mannose-conjugated liposomes: a novel strategy for treatment of melanoma.
    Chen D; Koropatnick J; Jiang N; Zheng X; Zhang X; Wang H; Yuan K; Siu KS; Shunnar A; Way C; Min WP
    J Immunother; 2014; 37(2):123-34. PubMed ID: 24509175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.
    Han Y; Chen Z; Yang Y; Jiang Z; Gu Y; Liu Y; Lin C; Pan Z; Yu Y; Jiang M; Zhou W; Cao X
    Hepatology; 2014 Feb; 59(2):567-79. PubMed ID: 23960017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDO inhibitor synergized with radiotherapy to delay tumor growth by reversing T cell exhaustion.
    Liu M; Li Z; Yao W; Zeng X; Wang L; Cheng J; Ma B; Zhang R; Min W; Wang H
    Mol Med Rep; 2020 Jan; 21(1):445-453. PubMed ID: 31746428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past.
    Shadbad MA; Hajiasgharzadeh K; Derakhshani A; Silvestris N; Baghbanzadeh A; Racanelli V; Baradaran B
    Front Immunol; 2021; 12():623639. PubMed ID: 33692796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression.
    Wobser M; Voigt H; Houben R; Eggert AO; Freiwald M; Kaemmerer U; Kaempgen E; Schrama D; Becker JC
    Cancer Immunol Immunother; 2007 Jul; 56(7):1017-24. PubMed ID: 17195079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA.
    Yen MC; Lin CC; Chen YL; Huang SS; Yang HJ; Chang CP; Lei HY; Lai MD
    Clin Cancer Res; 2009 Jan; 15(2):641-9. PubMed ID: 19147770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased indoleamine 2,3-dioxygenase expression in dendritic cells and role of indoleamine 2,3-dioxygenase-expressing dendritic cells in immune thrombocytopenia.
    Xu SQ; Wang CY; Zhu XJ; Dong XY; Shi Y; Peng J; Qin P; Sun JZ; Guo C; Ni H; Hou M
    Ann Hematol; 2012 Oct; 91(10):1623-31. PubMed ID: 22526360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer.
    Qian F; Villella J; Wallace PK; Mhawech-Fauceglia P; Tario JD; Andrews C; Matsuzaki J; Valmori D; Ayyoub M; Frederick PJ; Beck A; Liao J; Cheney R; Moysich K; Lele S; Shrikant P; Old LJ; Odunsi K
    Cancer Res; 2009 Jul; 69(13):5498-504. PubMed ID: 19491279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Der p 1 suppresses indoleamine 2, 3-dioxygenase in dendritic cells from house dust mite-sensitive patients with asthma.
    Maneechotesuwan K; Wamanuttajinda V; Kasetsinsombat K; Huabprasert S; Yaikwawong M; Barnes PJ; Wongkajornsilp A
    J Allergy Clin Immunol; 2009 Jan; 123(1):239-48. PubMed ID: 19058839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase.
    Mellor AL; Chandler P; Baban B; Hansen AM; Marshall B; Pihkala J; Waldmann H; Cobbold S; Adams E; Munn DH
    Int Immunol; 2004 Oct; 16(10):1391-401. PubMed ID: 15351783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.